Cystaran is a topical ophthalmic therapy that is used to treat a rare genetic disorder.
Leadiant Biosciences has chosen AllianceRx Walgreens Prime to be the exclusive specialty pharmacy and clinical support provider as it relaunches its rare disease drug Cystaran (cysteamine) ophthalmic solution. Cystaran is used to treat corneal cystine crystals in patients with cystinosis, a rare, multi-system genetic disorder that typically manifests in early childhood.
The two companies have partnered since 2014, and Leadiant recently relaunched Cystaran with revised packaging.
“Our organizations are aligned in wanting the best possible outcomes for the patients,” Tracey James, RPh, Senior Vice President, Pharmacy Services, at AllianceRx Walgreens Prime, said in a press release.
Cystinosis causes an abnormal accumulation of the amino acid cystine in various organs and tissues of the body including the eyes, kidneys, muscles, pancreas, and brain. The cystine accumulation causes widespread tissue and organ damage.
Cystinosis affects about 1 in 100,000 to 200,000 newborns worldwide, according to the National Institutes of Health. It is caused by mutations in the CTNS gene.
AllianceRx Walgreens Prime is a specialty and home delivery pharmacy. In January, URAC issued a reaccreditation for the specialty pharmacy services offered by AllianceRx Walgreens Prime.
Its customized Connected Care Cystaran program provides patient support and clinical interventions specific to each patient's self-reported issues. Through the program, pharmacists regularly connect with patients to address any issues they have.